Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel 24h vs 96h Infusion with Cisplatin in Ovarian Cancer (GOG-162)
NCT00002717Phase 3Completed
- Sponsor
- GOG Foundation
- Start
- Mar 1996
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in ovarian cancer and primary peritoneal cancer (PPC) (2 arms), sponsored by GOG Foundation. Primary endpoint: Overall Survival. Started Mar 1996; status: completed.
02
Drugs
paclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00002717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002717.